文献速递复苏、休克与脓毒症心脑血管急症

肾上腺素用于院外心脏骤停:随机对照试验的系统评价与Meta分析

Epinephrine for out of hospital cardiac arrest: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Resuscitation · 2019-01-24
一句话结论院外心脏骤停中,肾上腺素(标准或高剂量)较对照提高出院存活率(RR 1.16,95%CI 1.00-1.35)和良好神经功能结局(RR 1.24,95%CI 1.04-1.48)。

该系统评价与Meta分析纳入15项随机对照试验、共20716例院外心脏骤停成人患者,比较肾上腺素与对照治疗。肾上腺素与所有对照治疗合并比较时,出院存活率(RR 1.16,95%CI 1.00-1.35)和良好神经功能结局(RR 1.24,95%CI 1.04-1.48)改善,但入院存活率(RR 1.02,95%CI 0.75-1.38)和自主循环恢复(ROSC)(RR 1.13,95%CI 0.84-1.53)无差异。与安慰剂/无药物比较时,出院存活率(RR 1.34,95%CI 1.08-1.67)、ROSC(RR 2.03,95%CI 1.18-3.51)和入院存活率(RR 2.04,95%CI 1.22-3.43)增加,但良好神经功能结局无统计学显著差异(RR 1.22,95%CI 0.99-1.51)。作者结论认为院外心脏骤停应使用标准或高剂量肾上腺素。

要点

  • 院外心脏骤停成人中,肾上腺素与所有对照治疗合并比较,出院存活率RR 1.16(95%CI 1.00-1.35),良好神经功能结局RR 1.24(95%CI 1.04-1.48)。
  • 肾上腺素与安慰剂/无药物比较,ROSC的RR 2.03(95%CI 1.18-3.51),入院存活率RR 2.04(95%CI 1.22-3.43),出院存活率RR 1.34(95%CI 1.08-1.67)。
  • 肾上腺素与安慰剂/无药物比较,良好神经功能结局RR 1.22(95%CI 0.99-1.51),未达统计学显著。
  • 肾上腺素与所有对照治疗合并比较,入院存活率(RR 1.02,95%CI 0.75-1.38)和ROSC(RR 1.13,95%CI 0.84-1.53)无差异。
  • 作者结论:院外心脏骤停应使用标准或高剂量肾上腺素,因其改善出院存活率并带来有临床意义的结局。

适用人群与场景

  • 院外心脏骤停成人患者。

研究设计与关键结果

  • 系统评价与Meta分析纳入15项随机对照试验,共20716例院外心脏骤停成人患者,比较肾上腺素与对照治疗。
  • 肾上腺素与所有对照治疗合并比较:出院存活率RR 1.16(95%CI 1.00-1.35),良好神经功能结局RR 1.24(95%CI 1.04-1.48);入院存活率RR 1.02(95%CI 0.75-1.38)和ROSC(RR 1.13,95%CI 0.84-1.53)无差异。
  • 肾上腺素与安慰剂/无药物比较:出院存活率RR 1.34(95%CI 1.08-1.67),ROSC的RR 2.03(95%CI 1.18-3.51),入院存活率RR 2.04(95%CI 1.22-3.43);良好神经功能结局RR 1.22(95%CI 0.99-1.51),未达统计学显著。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析。
  • 检索MEDLINE和PubMed自建库至2018年8月,独立双人数据提取,采用Cochrane协作网标准评估偏倚风险。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为院外心脏骤停应使用标准或高剂量肾上腺素,因其改善出院存活率并带来有临床意义的结局。
  • 与安慰剂/无药物相比,肾上腺素增加ROSC、入院存活率和出院存活率,但良好神经功能结局未达统计学显著。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the effectiveness of epinephrine, compared with control treatments, on survival at admission, ROSC, survival at discharge, and a favorable neurologic outcome in adult patients during OHCA.

DATA SOURCE: MEDLINE and PubMed from inception to August 2018.

STUDY SELECTION: Randomized controlled trials (RCTs) on adult patients after OHCA treated with epinephrine versus controls.

DATA EXTRACTION: Independent, double-data extraction; risk of bias assessment with Cochrane Collaboration's criteria.

DATA SYNTHESIS: 15 RCTs representing 20 716 OHCA adult patients. Epinephrine, compared with all pooled treatments, was associated with a better survival rate to hospital discharge (RR: 1.16, 95% CI: 1.00-1.35) and a favorable neurologic outcome (RR: 1.24, 95% CI: 1.04-1.48). No difference was found in survival to hospital admission (RR: 1.02, 95% CI: 0.75-1.38) and ROSC when comparing epinephrine with all pooled treatments (RR: 1.13, 95% CI: 0.84-1.53). When epinephrine was compared with a placebo/no drugs, survival to hospital discharge (RR: 1.34, 95% CI: 1.08-1.67), ROSC (RR: 2.03, 95% CI: 1.18-3.51) and survival to hospital admission (RR: 2.04, 95% CI: 1.22-3.43) were increased, but there was not a favorable neurologic outcome (RR: 1.22, 95% CI: 0.99-1.51).

CONCLUSIONS: In OHCA, standard or high doses of epinephrine should be used because they improved survival to hospital discharge and resulted in a meaningful clinical outcome. There was also a clear advantage of using epinephrine over a placebo or no drugs in the considered outcomes.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Vargas M, Buonanno P, Iacovazzo C, et al. Epinephrine for out of hospital cardiac arrest: A systematic review and meta-analysis of randomized controlled trials. Resuscitation. 2019. PMID: 30685547. doi:10.1016/j.resuscitation.2019.01.016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。